The global neuroscience antibodies and assays market size was valued at USD 3.72 billion in 2024 and is expected to reach USD 5.86 billion, growing at a CAGR of 5.41% from 2025 to 2033. The market is driven by the rising prevalence of neurological and neurodegenerative disorders globally-conditions like Alzheimer’s, Parkinson’s, multiple sclerosis, neuroinflammation, psychiatric disorders, etc.
As populations age and as diagnostic capabilities improve, there is increasing demand for tools that can detect disease earlier and help in drug discovery. Also, regulatory pressures and funding from governments and institutions are growing, which support neuroscience R&D and hence require antibodies/assays as key enabling components. Growth is also being accelerated by rising government spending and R&D projects. One major factor propelling the market's expansion is the increasing incidence of Alzheimer's disease. The need for early and precise diagnostic tools keeps growing as the world's population ages. The 2024 Alzheimer's Association predicts that the number of Americans with Alzheimer's will increase dramatically and that dementia risk increases with age. The number of people 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050. The age group most vulnerable to Alzheimer's dementia, baby boomers (those born between 1946 and 1964), will all be 65 or older by 2030.
Furthermore, technological advancements are greatly improving MS diagnosis and monitoring, and during the forecast period, they are anticipated to generate significant growth opportunities in the MS diagnostics market. Early detection, patient monitoring, and symptom management have all been enhanced by cutting-edge technologies like MRI-based imaging, neurophysiological monitoring, smartphone applications, assistive robotic devices, and neurotherapeutic assessment methods like transcranial direct current stimulation (tDCS). One of the main factors propelling market expansion is the increasing incidence of MS worldwide and the corresponding rise in the need for prompt and precise diagnostic solutions. There were 2.3 million MS patients in 2013, 2.8 million in 2020, and 2.9 million in 2023, according to the MS International Federation.
Increased investment in R&D, especially in the creation of innovative imaging methods, biomarker assays, and digital monitoring platforms, supports market expansion even more. The global MS diagnostics market is also growing as a result of expanding government initiatives to improve access to diagnostic services, technological advancements, and improved healthcare infrastructure. To further the study of neurodegenerative diseases, Beckman Coulter Diagnostics introduced a new line of blood-based Research Use Only (RUO) biomarker immunoassays in January 2025. These tests are intended to evaluate important biomarkers that are becoming important markers in neurodegenerative diseases, such as Alzheimer's disease, including p-Tau217, GFAP, NfL, and APOE ε4.
Beckman Coulter's dedication to giving researchers top-notch instruments to identify and measure biomarkers with remarkable sensitivity and specificity is demonstrated by the launch of these assays. The assays support the development of early diagnostic techniques and individualized treatment plans by providing accurate measurement of these biomarkers, which contributes to a deeper understanding of disease mechanisms. These assays' compatibility with Beckman Coulter's Immunoassay Analyzers guarantees integration with current laboratory workflows, improving the efficacy and efficiency of research on neurodegenerative diseases.
Furthermore, by improving availability and competitive dynamics, major players' introduction of new products has been facilitating market expansion. For instance, the ultrasensitive biomarker detection company Quanterix Corporation announced in July 2022 that a laboratory-developed test (LDT) that measures phospho-Tau 181 (pTau-181) in plasma quantitatively has been validated. This test will aid in the diagnostic evaluation of Alzheimer's disease. This LDT uses a quantitative immunoassay format to measure the levels of pTau-181 in human plasma and was first made available for clinical use in the United States. During the forecast period, the market is expected to grow more quickly due to these developments in immunoassay-based diagnostics for neurological conditions.
Similarly, in November 2021, Fujirebio Europe NV launched two Alzheimer’s disease immunoassays on its Innotest platform, marking the first product release following its collaboration with Adx Neurosciences NV. The assays are designed to measure neuronal pentraxin-2 (NPTX2) and soluble triggering receptor expressed on myeloid cells 2 (STREM2), two biomarkers linked to synaptic dysfunction and neuroinflammation key processes associated with Alzheimer’s progression. These innovations are expected to complement ongoing therapeutic development efforts for Alzheimer’s disease. Consequently, the continued rollout of novel immunoassay solutions targeting neuroscience biomarkers is anticipated to significantly drive market growth over the coming years.
This product will be delivered within 1-3 business days.
As populations age and as diagnostic capabilities improve, there is increasing demand for tools that can detect disease earlier and help in drug discovery. Also, regulatory pressures and funding from governments and institutions are growing, which support neuroscience R&D and hence require antibodies/assays as key enabling components. Growth is also being accelerated by rising government spending and R&D projects. One major factor propelling the market's expansion is the increasing incidence of Alzheimer's disease. The need for early and precise diagnostic tools keeps growing as the world's population ages. The 2024 Alzheimer's Association predicts that the number of Americans with Alzheimer's will increase dramatically and that dementia risk increases with age. The number of people 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050. The age group most vulnerable to Alzheimer's dementia, baby boomers (those born between 1946 and 1964), will all be 65 or older by 2030.
Furthermore, technological advancements are greatly improving MS diagnosis and monitoring, and during the forecast period, they are anticipated to generate significant growth opportunities in the MS diagnostics market. Early detection, patient monitoring, and symptom management have all been enhanced by cutting-edge technologies like MRI-based imaging, neurophysiological monitoring, smartphone applications, assistive robotic devices, and neurotherapeutic assessment methods like transcranial direct current stimulation (tDCS). One of the main factors propelling market expansion is the increasing incidence of MS worldwide and the corresponding rise in the need for prompt and precise diagnostic solutions. There were 2.3 million MS patients in 2013, 2.8 million in 2020, and 2.9 million in 2023, according to the MS International Federation.
Increased investment in R&D, especially in the creation of innovative imaging methods, biomarker assays, and digital monitoring platforms, supports market expansion even more. The global MS diagnostics market is also growing as a result of expanding government initiatives to improve access to diagnostic services, technological advancements, and improved healthcare infrastructure. To further the study of neurodegenerative diseases, Beckman Coulter Diagnostics introduced a new line of blood-based Research Use Only (RUO) biomarker immunoassays in January 2025. These tests are intended to evaluate important biomarkers that are becoming important markers in neurodegenerative diseases, such as Alzheimer's disease, including p-Tau217, GFAP, NfL, and APOE ε4.
Beckman Coulter's dedication to giving researchers top-notch instruments to identify and measure biomarkers with remarkable sensitivity and specificity is demonstrated by the launch of these assays. The assays support the development of early diagnostic techniques and individualized treatment plans by providing accurate measurement of these biomarkers, which contributes to a deeper understanding of disease mechanisms. These assays' compatibility with Beckman Coulter's Immunoassay Analyzers guarantees integration with current laboratory workflows, improving the efficacy and efficiency of research on neurodegenerative diseases.
Furthermore, by improving availability and competitive dynamics, major players' introduction of new products has been facilitating market expansion. For instance, the ultrasensitive biomarker detection company Quanterix Corporation announced in July 2022 that a laboratory-developed test (LDT) that measures phospho-Tau 181 (pTau-181) in plasma quantitatively has been validated. This test will aid in the diagnostic evaluation of Alzheimer's disease. This LDT uses a quantitative immunoassay format to measure the levels of pTau-181 in human plasma and was first made available for clinical use in the United States. During the forecast period, the market is expected to grow more quickly due to these developments in immunoassay-based diagnostics for neurological conditions.
Similarly, in November 2021, Fujirebio Europe NV launched two Alzheimer’s disease immunoassays on its Innotest platform, marking the first product release following its collaboration with Adx Neurosciences NV. The assays are designed to measure neuronal pentraxin-2 (NPTX2) and soluble triggering receptor expressed on myeloid cells 2 (STREM2), two biomarkers linked to synaptic dysfunction and neuroinflammation key processes associated with Alzheimer’s progression. These innovations are expected to complement ongoing therapeutic development efforts for Alzheimer’s disease. Consequently, the continued rollout of novel immunoassay solutions targeting neuroscience biomarkers is anticipated to significantly drive market growth over the coming years.
Global Neuroscience Antibodies And Assays Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global neuroscience antibodies and assays market based on product, technology, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Instruments
Technology Outlook (Revenue, USD Million, 2021-2033)
- Immunoassays & immunochemistry
- Molecular Diagnostics
- Clinical Chemistry & other related detection platforms
- Other emerging / ultrasensitive platforms
End Use Outlook (Revenue, USD Million, 2021-2033)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Firms
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Neuroscience Antibodies and Assays Market: Methodology and Scope
Chapter 2. Neuroscience Antibodies and Assays Market: Executive Summary
Chapter 3. Neuroscience Antibodies and Assays Market Variables, Trends, & Scope
Chapter 4. Neuroscience Antibodies and Assays Market: Product Estimates & Trend Analysis
Chapter 5. Neuroscience Antibodies and Assays Market: Technology Estimates & Trend Analysis
Chapter 6. Neuroscience Antibodies and Assays Market: End Use Estimates & Trend Analysis
Chapter 7. Neuroscience Antibodies and Assays Market: Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Neuroscience Antibodies and Assays market report include:- Thermo Fisher Scientific
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- F. Hoffmann-La Roche
- Cell Signaling Technology, Inc.
- BioLegend, Inc.
- Exalenz Bioscience Ltd (meridian bioscience)
- Abcam Plc
- Rockland Immunochemicals, Inc.
- GenScript
- Santa Cruz Biotechnology, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 3.72 Billion |
| Forecasted Market Value ( USD | $ 5.86 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
